Line 1: |
Line 1: |
| {{unfinished}} | | {{unfinished}} |
− |
| |
− | *[[Adenoma|Adenomas]] and [[Carcinoma|carcinomas]] deerived from beta cells
| |
− | *Respond rapidly to iv glucose
| |
− | *Can be identified by immunocytochemical means
| |
− | *Dogs 5-12 years of age most commonly affected
| |
− | *Older cattle, associated with periodic convulsions
| |
− | ====Clinical signs====
| |
− | *Hyperinsulinism
| |
− | *Hypoglycaemia - often episodic
| |
− | **Neurologic signs - stupor, confusion, coma, seizures, peripheral neuropathy may also develop
| |
− |
| |
− |
| |
− |
| |
− |
| |
− |
| |
| | | |
| ==Description== | | ==Description== |
Line 23: |
Line 8: |
| | | |
| ==Signalment== | | ==Signalment== |
− | Insulinomas occur most commonly in middle-aged or older dogs of the larger breeds. There is no sex predilection and the condition occurs less commonly in cats. | + | Insulinomas occur most commonly in middle-aged or older dogs of the larger breeds. There is no sex predilection and the condition occurs less commonly in cats. Older cattle may rarely develop insulin-secreting tumours. |
| | | |
| ==Diagnosis== | | ==Diagnosis== |
Line 51: |
Line 36: |
| *'''Serum fructosamine levels''' can also be assessed to gauge whether the animal has been persistently hypoglycaemic over the previous 2-3 weeks. A level <250-350 umol/l is suggestive of insulinoma | | *'''Serum fructosamine levels''' can also be assessed to gauge whether the animal has been persistently hypoglycaemic over the previous 2-3 weeks. A level <250-350 umol/l is suggestive of insulinoma |
| | | |
− | ===Histopathology=== | + | ===Pathology=== |
| This is needed for definitive confirmation of the diagnosis. The following features may be identified: | | This is needed for definitive confirmation of the diagnosis. The following features may be identified: |
| *Usually single, or less often multiple, small (1-3cm) spherical nodules, yellow to dark red, in one or more lobes | | *Usually single, or less often multiple, small (1-3cm) spherical nodules, yellow to dark red, in one or more lobes |
| *Small islets of acinar tissue are sometimes present within the neoplasm | | *Small islets of acinar tissue are sometimes present within the neoplasm |
| + | *Pancreatic beta cells can readily be identified using immunocytochemistry |
| | | |
| ===Diagnostic Imaging=== | | ===Diagnostic Imaging=== |
Line 65: |
Line 51: |
| ==Treatment== | | ==Treatment== |
| ===Emergency Stabilisation=== | | ===Emergency Stabilisation=== |
− | *In the event of a hypoglycaemic episode, a dextrose bolus should be given immdediately.
| + | In the event of a hypoglycaemic episode, a bolus of 50% dextrose solution should be given immediately. Glucose syrup can also be rubbed onto the gums of an affected animal or a meal could be provided and this approach may reduce the risk of rebound hypoglycaemia encountered with administration of 50% dextrose solution. Intra-venous fluid therapy can then be maintained using 2.5% dextrose solution. |
− | *This should be followed by intravenous fluid therapy with 2.5% dextrose.
| |
− | *Alternatively, if the patient is able to eat, frequent feedings can be used instead of dextrose fluid therapy. This may be preferred to avoid the risk of rebound hypoglycaemia.
| |
| | | |
− | ===Medical=== | + | ===Medical Management=== |
− | This is more suitable for patients in which surgery has been declined or when surgery is inappropriate or fails due to the presence of metastasis. | + | This is suitable for patients in which surgery has been declined or when clinical signs recur after surgical treatment due to the presence of metastases. A suitable regime would include: |
| *'''Small and frequent meals''' (3-6 times/day) of with high fat and protein content and some complex carbohydrate. | | *'''Small and frequent meals''' (3-6 times/day) of with high fat and protein content and some complex carbohydrate. |
| *'''Exercise restriction'''. | | *'''Exercise restriction'''. |
− | *[[Steroids|'''Glucocorticoids''']] such as prednisolone may be prescribed to increase hepatic gluconeogenesis and to decrease cellular glucose uptake. | + | *[[Steroids|'''Glucocorticoids''']] such as prednisolone prescribed to increase hepatic gluconeogenesis and to decrease cellular glucose uptake. |
− | *'''Diazoxide''', an oral hyperglycaemic drug, may be used to inhibit pancreatic insulin secretion and tissue glucose uptake. | + | *'''Diazoxide''', an oral hyperglycaemic drug, used to inhibit pancreatic insulin secretion and tissue glucose uptake. |
| + | *'''Octreotide''', a somatostatin analogue which reduces the synthesis of insulin, is rarely used for management of insulinomas. |
| | | |
− | ===Surgery=== | + | ===Surgical Management=== |
− | A '''partial pancreatectomy''' is suitable for patients with a solitary tumour and any suspected metastases may be removed or biopsied at the same time. Possible post-operative complication include: | + | A '''partial pancreatectomy''' is suitable for patients with a solitary tumour and any suspected metastases may be removed or biopsied during the procedure. An intra-operative ultrasound scan can be performed if the mass is not evident when the pancreas has been exposed. Possible post-operative complications include: |
− | *'''Persistent hypoglycaemia''', probably due to the presence of unidentified metastases | + | *'''Persistent hypoglycaemia''', probably due to the presence of unidentified metastases. |
− | *[[Pancreatitis - Dog and Cat|'''Pancreatitis]]''' or '''Diabetes mellitus''' due to disruption to the pancreatic parenchyma during the procedure | + | *[[Pancreatitis - Dog and Cat|'''Pancreatitis]]''' or '''Diabetes mellitus''' due to disruption to the pancreatic parenchyma during the procedure. |
− | *'''Epilepsy''' and '''diffuse polyneuropathy''' due to chronic hypoglycaemia | + | *'''Epilepsy''' and '''diffuse polyneuropathy''' due to chronic hypoglycaemia. |
| + | *'''Duodenal necrosis and perforation''' as the cranial pancreatico-duodenal artery may be disrupted when the right limb of the pancreas is dissected away the duodenum. |
| | | |
| ==Prognosis== | | ==Prognosis== |
− | This is dependent on the WHO staging of the tumour. A stage I and II can expect a median survival time of 18 months whereas it is only 6 months for a stage III. Patients suitable for surgical excision has better prognosis than those treated medically. | + | This is related to the WHO stage of the tumour at diagnosis. An animal with a stage I and II neoplastic process could expect a median survival time of 18 months but this falls to only 6 months for an animal with stage III disease. Patients which undergo surgery to remove an insulinoma have a better prognosis than those treated medically but the condition will recur invariably after surgical removal. Those animals which show a recurrence of clinical signs after surgery may then be treated medically, an approach that produces a significant increase in median survival time (from approximately 2 years to 4 years). |
| | | |
| | | |
| ==References== | | ==References== |
| + | *Polton GA, White RN, Brearley MJ, Eastwood JM (2007) '''Improved survival in a retrospective cohort of 28 dogs with insulinoma.''' ''J Small Anim Pract. 2007 Mar;48(3):151-6.'' |
| *Ettinger, S.J. and Feldman, E. C. (2000) '''Textbook of Veterinary Internal Medicine Diseases of the Dog and Cat Volume 2''' (Fifth Edition) ''W.B. Saunders Company''. | | *Ettinger, S.J. and Feldman, E. C. (2000) '''Textbook of Veterinary Internal Medicine Diseases of the Dog and Cat Volume 2''' (Fifth Edition) ''W.B. Saunders Company''. |
| *Fossum, T. W. et. al. (2007) '''Small Animal Surgery (Third Edition)''' ''Mosby Elsevier'' | | *Fossum, T. W. et. al. (2007) '''Small Animal Surgery (Third Edition)''' ''Mosby Elsevier'' |